Fig. 2: Screening of ferroptosis-inducing compounds across patient-derived xenograft organoid NB models.
From: Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma
A Analysis of sensitivity to COJEC chemotherapy displayed by the four NB PDX-derived organoid models (LU-NB-1, LU-NB-2, LU-NB-3, and LU-NB-3R). Two different treatments were evaluated (COJEC Low and COJEC High). Statistical analysis with One-way ANOVA and T-test with Tukey multiple comparison correction (***P-value < 0.001). B NB cell viability and cell death data for 16 ferroptosis-inducing compounds across the four NB organoid models treated for 48 h. Data for the four most successful drugs across all models are marked in color (RSL3 red, Auranofin green, ML162 blue, Salinomycin purple); the rest are presented in grey. C Immunocytofluorescence analysis of ferroptosis markers CD71 and 4HNE for the four selected drugs from (B), untreated control, and COJEC chemotherapy in laminin-attached PDX1-derived organoids treated for 24 h. Control 1% DMSO, Auranofin 1 µM, RLS3 1.5 µM, ML162 0.1 µM, Salinomycin 0.25 µM, COJEC High Dose. CD71 = green, 4HNE = magenta, nuclear DAPI staining = blue. Scale bar = 50 μm. D Flow cytometry-based analysis of lipid peroxidation for LU-NB-1 organoids treated with the four selected drugs from (B), untreated control, and COJEC for 24 h. Control 1% DMSO, Auranofin 5 µM, RLS3 4 µM, ML162 4 µM, Salinomycin 5 µM, COJEC High Dose.
